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 Compounds synthesized for the first
time.
 And show antitumor activity.
 The effective dose is 100 lM.g r a p h i c a l a b s t r a c t
The chalcone-cyclophosphazene compounds containing dioxybiphenyl groups (2a–2h) were synthesized.
In vitro anti-carcinogenic activities of these compounds were performed by using MTT assay against PC-3
and LNCaP cancer cell lines. Results, these compounds (2a–2h) were found to have anti-tumor activity
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PC-3 and LNCaPa b s t r a c t
2,2-Dichloro-4,4,6,6-bis[spiro(20,200-dioxy-10 ,100-biphenylyl]cyclotriphosphazene (2) was synthesized
from hexachlorocyclotriphosphazene (HCCP) and 2,20-dihydroxybiphenyl. The mixed substituent chal-
cone/dioxybiphenyl cyclophosphazenes (2a–h) were obtained from the reactions of (2) with hydroxy
chalcone compounds in K2CO3/acetone system. The chalcone-cyclophosphazene compounds were char-
acterized by elemental analysis, FT-IR, 1H, 13C, 31P NMR techniques. In vitro anti-carcinogenic activities of
all compounds were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. Anti-carcinogenic activity of the compounds (2a–h) against androgen-dependent (LNCaP)
and independent (PC-3) human prostate cancer cell lines were investigated. Our results indicate that
the chalcone-phosphazene compounds (2a–h) have anti-carcinogenic activity on PC-3 and LNCaP cell
lines (p < 0.05). The effective dose of the compounds was determined as 100 lM.
 2015 Elsevier B.V. All rights reserved.Introduction
Phosphazenes are molecules which contain AP@NA bonds.
There are three important types of phosphazenes, such as linear,
2 A.O. Görgülü et al. / Journal of Molecular Structure 1087 (2015) 1–10cyclic and poly. Trimer, tetramer and linear polyphosphazenes are
the most known and studied types of phosphazenes [1].
The phosphazene derivatives have various physical and biologi-
cal properties, for example liquid crystals [2,3], electrical conduc-
tivity [4], flame retardants [5–7], electrolytes for rechargeable
batteries [8], fire resistant materials [9], dielectric properties [10],
biomedical applications [11,12], antimicrobial, antibacterial
[13–18], anti-leukemic [19] and strong anti-tumor activity [20–27].
Chalcones are compounds that can be prepared by the Claisen–
Schmidt condensation reaction [28,29]. Because of the ketoviny-
lenic group in chalcones and their analogs, they exhibit numerous
physical and biological properties, for instance optical and fluores-
cence properties [30,31], dielectric properties [32,33], antioxidant
and soybean lipoxygenase inhibitory activity [34], antimicrobial
activity [35], Anti-HIV activity [36], antibacterial activity [37],
anti-inflammatory [38] and anti-cancer activities [39–44].
The synthesis of different phosphazene compounds has been
reported [13,45–53] but there are only four articles about synthesis
of the phosphazene compounds bearing chalcone groups [10,54–
56], there are, however, no studies about synthesis of dioxybiphe-
nyl substituted chalcone-cyclophosphazene compounds. The
cyclotriphosphazenes bearing 2,20-dihydroxybiphenyl are much
more stable to hydrolysis and thermal decomposition than hexa-
chlorocyclotriphosphazene [1].
In this study, the chalcone compounds containing AOH groups
were synthesized. And then these chalcone compounds (1a–h)
were reacted with 2,2-dichloro-4,4,6,6,-bis[spiro(20,200-dioxy-
10,100-biphenylyl)]cyclotriphosphazene in order to get substituted
products. As a result, cyclophosphazenes bearing 2,20-dioxybiphe-
nyl groups and chalcone compounds were synthesized and charac-
terized by elemental analysis, FT-IR, 1H, 13C, 31P NMR techniques.
Antitumor properties of these compounds were investigated by
MTT ([3-(4,5-dimethylthiazol)-2-yl]-2,5-diphenyl-2H-tetrazolium
bromide]) assay. The MTT assay is a simple procedure to determine
living and growing cells without using radioactivity. Our results
indicate that the chalcone-phosphazene compounds displayed
potential antitumor activity towards on human prostate cancer cell
lines (PC-3 and LNCaP).
Experimental
Materials and methods
Solvents and other liquids were purified by traditional methods.
Hexachlorocyclotriphosphazene, N3P3Cl6 (TCI), was crystallized
from n-hexane. The chemicals were purchased from Merck and
Sigma Aldrich. All reactions were monitored using thin-layer chro-
matography (TLC). The prostate carcinoma (PC-3 and LNCaP) and
human breast (MCF-7) cancer cell lines were retrieved from the
American Type Culture Collection (ATCC). Calf serum, trypsin, pen-
icillin and streptomycin were purchased from Hyclone (Waltham,
MA, USA).
FT-IR spectra were recorded on Perkin Elmer FT-IR spectrome-
ter. Microanalysis was carried out by a LECO 932 CHNS-O appara-
tus. 1D (1H, 13C, 13C APT and 31P NMR) spectra were recorded using
a Bruker DPX-400 spectrometer. The 1H, 13C and 31P NMR chemical
shifts were measured using TMS as an internal standard, whereas
those for 31P were measured using 85% H3PO4 as an external stan-
dard. For the NMR studies acetone-d6 was used as solvent for the
compounds 2a and 2d. The chloroform-d was used as solvent for
the compounds 2b, 2c, 2e, 2f, 2g and 2h.
Synthesis
40-Hydroxy chalcone compounds were prepared by reaction of
40-hydroxyacetophenone with various benzaldehydes [28,29].2,2-Dichloro-4,4,6,6-bis[spiro(20,200-dioxy-100,100-biphenyl]cyclotri-
phosphazene (2) was made as defined by Carriedo et al. [57]. The
reaction of [N3P3Cl6] with the 2,20-dihydroxybiphenyl took place
under inert atmosphere.
Preparation of substituted chalcone-phosphazenes
Chalcone-phosphazene compounds (2a–2h) were synthesized
by similar methods; therefore, the experimental method for the
synthesis of these compounds is only explained in detail for the
first case.
Synthesis of 2,2-(40-oxychalcone)-4,4,6,6-bis[spiro(20,200-dioxy-10,100-
biphenylyl] cyclotriphosphazene (2a). A mixture of compound 2
(1.0 g, 1.75 mmol) and K2CO3 (0.97 g, 7.0 mmol) in 50 mL dry
acetone was slowly added, over 0.5 h, to a stirred solution of
40-hydroxychalcone (1a) (0.9 g, 4.03 mmol) in 20 mL of dry acetone
at 0 C and then refluxed for 7 h. The solvent was evaporated. The
residue was extracted with CH2Cl2 (4  25 mL) and then washed
with 5% KOH solution four times and then dried over anhydrous
magnesium sulfate. The solvent was concentrated on a rotary
evaporator. After the solvent was removed, a white solid (2a)
formed 1.49 g (90%). Anal. Calc. for C54H38N3O8P3 (MW = 949.82):
C, 68.28; H, 4.03; N, 4.42. Found: C, 68.02; H, 4.12; N, 4.49%. IR
(KBr, cm1): 3061 and 3027 mCAH(Ar.), 2933 mCAH(Aliphatic), 1664 mC@O,
1605, 1576 and 1567 mC@C, 1175 and 1206 mP@N, 1273 mPANAP, 936
mPAOAC. 31P NMR (Aceton-d6) d/ppm: 25.02 (2P, d, Pa(O2C12H8)),
9.62 (1P, t, Pb(O4C30H22)). 1H NMR (Aceton-d6) d/ppm: 8.40 (4H,
d, H9), 8.12 (4H, d, H13), 7.98–7.76 (10H, m, H15, H16 and H17),
7.68 (2H, d, H12), 7.62 (4H, d, H3), 7.53–7.42 (8H, m, H4 and H5),
7.24 (4H, d, H6), 7.0 (4H, d, H8). 13C NMR (Aceton-d6) d/ppm:
187.66 C11, 153.94 C7, 147.72 C1, 144.06 C13, 135.47 C14, 134.90
C10, 130.52 C9, 129.88 C5, 129.60 C3, 128.76 C16, 128.53 C15,
128.32 C2, 128.29 C17, 126.33 C4, 121.61 C6, 121.13 C12, 115.13 C8.
Synthesis of 2,2-(20-oxy-2-methylchalcone)-4,4,6,6-bis[spiro(20,200-
dioxy-10,100-biphenylyl]cyclotriphosphazene (2b). 40-Hydroxy-2-
methylchalcone (1b) (0.95 g, 4.03 mmol), 9 h. Yield: 1.27 g, 75%.
Anal. Calc. for C56H42N3O8P3 (MW = 977.87): C, 68.78; H, 4.33; N,
4.30. Found: C, 68.82; H, 4.26; N, 4.35%. IR (KBr, cm1): 3063 and
3027 mCAH(Ar.), 2947 and 2924 mCAH(Aliphatic), 1662 mC@O, 1597,
1500 and 1477 mC@C, 1175 and 1203 mP@N, 1274 mPANAP, 936 mPAOAC.
31P NMR (chloroform-d) d/ppm: 25.41 (2P, d, Pa(O2C12H8)), 8.93
(1P, t, Pb(O4C32H26)). 1H NMR (chloroform-d) d/ppm: 8.15–8.20
(6H, m, H9, H13), 7.74 (2H, d, H12), 7.54–7.56 (8H, m, H3 and H5),
7.52 (2H, d, H19), 7.40–7.44 (4H, m, H17 and H18), 7.33–7.37 (6H,
m, H4 and H16), 7.28 (4H, d, H6), 7.14 (4H, d, H8), 2.51 (6H, s,
H20). 13C NMR (chloroform-d) d/ppm: 189.12 C11, 154.29 C7,
147.96 C1, 142.76 C13, 138.49 C15, 135.35 C14, 133.82 C10, 130.99
C16, 130.48 C9, 130.43 C17, 129.84 C5, 129.71 C3, 128.68 C2,




methylchalcone (1c) (0.95 g, 4.03 mmol), 8 h. Yield: 1.19 g, 70%.
Anal. Calc. for C56H42N3O8P3 (MW = 977.87): C, 68.78; H, 4.33; N,
4.30. Found: C, 68.70; H, 4.35; N, 4.39%. IR (KBr, cm1): 3062 and
3031mCAH(Ar.), 2954 and 2920mCAH(Aliphatic), 1663 mC@O, 1601, 1584,
1500 and 1477mC@C, 1175 and 1201mP@N, 1273mPANAP, 936 mPAOAC.
31P NMR (chloroform-d) d/ppm: 24.83 (2P, d, Pa(O2C12H8)), 8.99
(1P, t, Pb(O4C32H26)). 1H NMR (chloroform-d) d/ppm: 8.14–8.16
(6H, m, H9, H13), 7.83 (2H, d, H12), 7.54–7.58 (8H, m, H3 and H5),
7.49 (2H, d, H19), 7.40–7.44 (4H, m, H17 and H18), 7.32–7.37 (6H,
m, H4 and H15), 7.28 (4H, d, H6), 7.14 (4H, d, H8), 2.43 (6H, s, H20).
13C NMR (chloroform-d) d/ppm: 189.29 C11, 154.25 C7, 147.97 C1,
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Scheme 1. General presentation of the all reactions.
A.O. Görgülü et al. / Journal of Molecular Structure 1087 (2015) 1–10 3C9, 129.84 C5, 129.71 C3, 129.10 C17, 128.90 C18, 128.68 C2, 126.25 C4,
125.81 C19, 121.77 C6, 121.30 C12, 115.43 C8, 21.37 C20.
Synthesis of 2,2-(40-oxy-4-methylchalcone)-4,4,6,6-bis[spiro(20,200-
dioxy-10,100-biphenylyl] cyclotriphosphazene (2d). 40-Hydroxy-4-
methylchalcone (1d) (0.95 g, 4.03 mmol), 6 h. Yield: 1.46 g, 86%.
Anal. Calc. for C56H42N3O8P3 (MW = 977.87): C, 68.78; H, 4.33; N,
4.30. Found: C, 68.72; H, 4.35; N, 4.38%. IR (KBr, cm1): 3063 and
3027 mCAH(Ar.), 2950 mCAH(Aliphatic), 1662 mC@O, 1602, 1567 and 1500
mC@C, 1173 and 1200 mP@N, 1273 mPANAP, 936 mPAOAC. 31P NMR (Ace-
ton-d6) d/ppm: 25.03 (2P, d, Pa(O2C12H8)), 9.63 (1P, t, Pb(O4C32H26)).
1H NMR (Aceton-d6) d/ppm: 8.38 (4H, d, H9), 8.11 (2H, d, H13), 7.67
(2H, d, H12), 7.61 (4H, d, H3), 7.53–7.41 (8H, m, H4 and H5), 7.44 (4H,
d, H15), 7.23–7.21 (8H, m, H6 and H16), 7.02 (4H, d, H8), 2.39 (6H, s,
H18). 13C NMR (Aceton-d6) d/ppm: 187.64 C11, 153.87 C7, 147.72
C1, 144.15 C13, 140.81 C17, 135.59 C14, 132.18 C10, 130.46 C9,
129.88 C5, 129.60 C3, 129.44 C16, 128.58 C2, 128.33 C15, 126.33 C4,
121.65 C6, 121.10 C12, 115.11 C8, 20.42 C18.
Synthesis of 2,2-(40-oxy-2-fluorochalcone)-4,4,6,6-bis[spiro(20,200-
dioxy-10,100-biphenylyl] cyclotriphosphazene (2e). 40-Hydroxy-2-fluorochalcone (1e) (1 g, 4.03 mmol), 5 h. Yield: 1.55 g, 90%. Anal.
Calc. for C54H36F2N3O8P3 (MW = 985.80): C, 65.79; H, 3.68; N,
4.26. Found: C, 65.83; H, 3.73; N, 4.22%. IR (KBr, cm1): 3067 and
3041 mCAH(Ar.), 2962 and 2924 mCAH(Aliphatic), 1665 mC@O, 1598,
1507 and 1476 mC@C, 1175 and 1204 mP@N, 1274 mPANAP, 936 mPAOAC.
31P NMR (chloroform-d) d/ppm: 25.02 (2P, d, Pa(O2C12H8)), 9.62
(1P, t, Pb(O4C30H20)). 1H NMR (chloroform-d) d/ppm: 8.13–8.17
(6H, m, H9, H13), 7.83 (2H, d, H12), 7.31–7.66 (20H, m, H3, H4, H5,
H16, H17, H18 and H19), 7.12–7.18 (8H, m, H6 and H8). 13C NMR
(chloroform-d) d/ppm: 188.97 C11, 165.40 and 162.89 C15, 154.31
C7, 147.90 C1, 143.84 C13, 135.24 C14, 131.04 C10, 130.50 C9,
130.46 C17, 129.85 C5, 129.74 C3, 128.67 C2, 126.46 C4, 121.75 C6,
121.37–121.32 C18 and C19, 121.27 C12, 116.32 C8, 116.10 C16.
Synthesis of 2,2-(40-oxy-3-fluorochalcone)-4,4,6,6-bis[spiro(20,200-
dioxy-10,100-biphenylyl]cyclotriphosphazene (2f). 40-Hydroxy-3-flu-
orochalcone (1f) (1 g, 4.03 mmol), 5 h. Yield: 1.21 g, 70%. Anal. Calc.
for C54H36F2N3O8P3 (MW = 985.80): C, 65.79; H, 3.68; N, 4.26.
Found: C, 65.73; H, 3.72; N, 4.30%. IR (KBr, cm1): 3065 and
3038mCAH(Ar.), 2962 and 2925mCAH(Aliphatic), 1666 mC@O, 1608, 1582,
1501 and 1477mC@C, 1174 and 1201mP@N, 1273mPANAP, 936 mPAOAC.
2compoundfor,H-:R a R : 2-CH3 2compoundfor, b
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Scheme 2. Structures of the compounds 2a–2h.
4 A.O. Görgülü et al. / Journal of Molecular Structure 1087 (2015) 1–1031P NMR (chloroform-d) d/ppm: 24.79 (2P, d, Pa(O2C12H8)), 8.91
(1P, t, Pb(O4C30H20)). 1H NMR (chloroform-d) d/ppm: 8.42 (4H, d,
H9), 8.32 (2H, s, H15), 8.10 (2H, d, H13), 7.88 (2H, d, H19), 7.80
(2H, d, H12), 7.71 (2H, t, H18), 7.44–7.58 (16H, m, H3, H4and H5),
7.28–7.33 (6H, m, H6 and H17), 7.23 (4H, d, H8). 13C NMR (chloro-
form-d) d/ppm: 188.83 C11, 164.29 and 161.84 C16, 154.34 C7,
147.94 C1, 143.62 C13, 137.06 C15, 135.05 C14, 130.63–130.53 C9
and C10, 129.85 C5, 129.75 C3, 128.67 C2, 126.30 C4, 124.63 C19,
122.80 C18, 121.73 C6, 121.32 C12, 117.44–117.65 C17, 114.45–
114.66 C8.Synthesis of 2,2-(40-oxy-4-fluorochalcone)-4,4,6,6-bis[spiro(20,200-
dioxy-10,100-biphenylyl]cyclotriphosphazene (2g). 40-Hydroxy-4-flu-
orochalcone (1g) (1 g, 4.03 mmol), 5 h. Yield: 1.52 g, 88%. Anal.
Calc. for C54H36F2N3O8P3 (MW = 985.80): C, 65.79; H, 3.68; N,
4.26. Found: C, 65.81; H, 3.60; N, 4.33%. IR (KBr, cm1): 3065 and
3038mCAH(Ar.), 2969 and 2927mCAH(Aliphatic), 1666 mC@O, 1605, 1576,
1500 and 1477mC@C, 1175 and 1.202mP@N, 1275mPANAP, 936 mPAOAC.31P NMR (chloroform-d) d/ppm: 24.80 (2P, d, Pa(O2C12H8)), 8.92
(1P, t, Pb(O4C30H20)). 1H NMR (chloroform-d) d/ppm: 8.14–17
(4H, d, H9), 7.98 (2H, d, H13), 7.71 (2H, d, H12), 7.54–7.56 (8H, m,
H3 and H15), 7.33–7.44 (8H, m, H4 and H5), 7.17–7.25 (8H, m, H6
and H16), 7.14 (4H, d, H8).
13C NMR (chloroform-d) d/ppm: 189.14 C11, 160.54 and 160.03
C17, 154.38 C7, 147.96 C1, 137.86 C13, 135.13 C14, 132.03 C10, 130.55
C9, 129.95 C15, 129.84 C5, 129.71 C3, 129.68 C2, 126.26 C4, 121.77
C6, 121.34 C12,116.47 C16, 116.25 C8.Synthesis of 2,2-(40-oxy-2-chlorochalcone)-4,4,6,6-bis[spiro(20,200-
dioxy-10,100-biphenylyl]cyclotriphosphazene (2h). 40-Hydroxy-2-
chlorochalcone (1h) (0.9 g, 3.48 mmol), 10 h. Yield: 1.15 g, 65%.
Anal. Calc. for C54H36Cl2N3O8P3 (MW = 1018.71): C, 63.67; H, 3.56;
N, 4.12. Found: C, 63.72; H, 3.50; N, 4.18%. IR (KBr, cm1): 3065
and 3031 mCAH(Ar.), 2960 and 2925 mCAH(Aliphatic), 1665 mC@O, 1602,
1564 and 1500 mC@C, 1179 and 1207 mP@N, 1272 mPANAP, 935 mPAOAC.





























Fig. 1. 31P NMR spectrum of compound 2b (chloroform-d).
A.O. Görgülü et al. / Journal of Molecular Structure 1087 (2015) 1–10 5t, Pb(O4C30H20)). 1H NMR (chloroform-d) d/ppm: 8.26 (2H, d, H13),
8.15 (4H, d, H9), 7.79 (2H, dd, H19), 7.32–7.56 (24H, m, H3, H4, H5,
H6, H12, H16, H17 and H18), 7.14 (4H, d, H8). 13C NMR (chloroform-
d) d/ppm: 189.08 C11, 154.39 C7, 147.95 C1, 140.91 C13, 135.57 C15,
135.05 C14, 133.17 C16, 131.30 C10, 130.60 C9, 130.36 C17, 129.84
C5, 129.71 C3, 128.68 C2, 127.85 C19, 127.13 C18, 126.26 C4, 121.76
C6, 121.28 C12, 117.22 C8.In vitro anticancer activity
Human breast cancer (MCF-7) and human prostate cancer (PC-3
and LNCaP) cell lines were preserved in Dulbecco’s modified
Eagle’s medium (DMEM) culture medium supplemented with
4 mM L-glutamine, with 4500 mg/L glucose (10% heat-inactivated
fetal bovine serum, 100 U/mL penicillin–streptomycin), with addi-
tion of 10 mM non-essential amino acids for culture of breast can-
cer cells. The cell lines were preserved at 37 C in 5% CO2
humidified incubator. The cytotoxicity effects of phosphazene
compounds were determined against human breast cancer (MCF-
7) and human prostate cancer (PC-3 and LNCaP) cell lines by using
MTT ([3-(4,5-dimethylthiazol)-2-yl]-2,5-diphenyl-2H-tetrazolium
bromide]) assay method [58–61].
The yellow MTT was transformed to a dark blue formazan prod-
uct that was determined by a micro plate reader. The MTT assay is a
simple procedure to determine living and growing cells. Breast and
prostate cancer cells were plated in triplicate in 96-well flat bottom
tissue culture plates. These cells treated with different concentra-
tions (1, 5, 25, 50 and 100 lM) of the chalcone-phosphazene com-
pounds. The culture plate cells were incubated for 24 h at 37 C in
5% CO2 humidified incubator. MTT (0.005 g/mL in phosphate buffersaline) was added to the cell culture and incubated for 4 h. The for-
mazan that occurred from the reaction of mitochondria with MTT
were dissolved in isopropanol (0.04 N 100 mL). All plates were read
at 570 nm by micro plate reader (Biotek Synergy). Each data point is
reported as an average of 10 measurements. All cellular results
were measured against control cells [58–61].
All data were expressed as mean ± SD. Normality was tested by
Shapiro Wilk Test. Homogeneity of variances was measured using
Levene’s method. Groups were compared by one-way analysis of
variance. Because of nonhomogeneity of variances, Tamhane T2
test was used for multiple comparisons. P < 0.05 was considered
as significant.Results and discussion
Synthesis
40-hydroxy chalcones (1a–h) were obtained from the reaction of
40-hydroxyacetophenone with substitute benzaldehydes [28,29].
2,2-Dichloro-4,4,6,6-bis[spiro(20,200-dioxy-100,100-biphenyl]cyclo-
triphosphazene (2) was synthesized from the reaction of hexachlo-
rocyclotriphosphazene (HCCP) with 2,20-dihydroxybiphenyl under
dry argon [54]. The reactions of (2) with 2.1 equiv. of hydroxy chal-
cones in the presence of K2CO3 in acetone gave the substituted
products (2a–h). The chalcone-phosphazene compounds were
generally obtained in high yields. These compounds were charac-
terized by elemental analysis, FT-IR, 1H, 13C, 31P NMR spectroscopy
techniques. General presentation of the reactions is shown in








































































































































Fig. 2. 1H NMR spectrum of compound 2b (chloroform-d).
6 A.O. Görgülü et al. / Journal of Molecular Structure 1087 (2015) 1–10FT-IR spectroscopy
The AP@N stretching vibrations, which are observed between
1173 and 1207 cm–1, are characteristic of the cyclophosphazene
compounds. The absence of the OH stretching vibration in the
FT-IR spectra of 2a–2h indicates that all hydrogen atoms of the
OH groups have been replaced. In the FT-IR spectra of 2a–2h, the
PAOAC stretching vibrations which were observed between 935
and 937 cm1 and the C@O stretching vibrations which were
observed between 1662 and 1666 cm1 also indicate the substitute
chalcone-phosphazene compounds.NMR spectroscopy
The 31P NMR data for 2a–2h are given in experimental section
(AB2 system). There are two peaks in the 31P NMR spectra of
chalcone substituted phosphazene compounds (2a–2h). The 31P
NMR spectra of 2a–2h give two sets of peaks around d = 8.91 and
25.41 ppm in a triplet-doublet. The 31P NMR spectrum of 2b is
depicted in Fig. 1.
The 1H and 13C NMR data also confirm the structures of 2a–2h
(Scheme 2). In the 1H NMR spectra of 2a–2h, the absence of the OH
protons indicates the chalcone substitute phosphazene products.
The 1H NMR spectra of 2b is depicted in Fig. 2. The methyl protons
for the compounds 2b, 2c, and 2d were observed at 2.51, 2.43 and
2.39 ppm respectively. The aromatic protons for all the compounds
appear between 7.0 and 8.42 ppm. AOH peaks of the chalcone
groups were not observed in 1H NMR spectrum of compounds
2a–2h.
The detailed 13C NMR spectral data were given in experimental
section. The 13C NMR spectrum of 2b is depicted in Fig. 3 as anexample. The carbonyl carbon atoms (C@O, C11) for 2a–2h were
observed at 187.66, 189.12, 189.29, 187.64, 188.97, 188.83,
189.14 and 189.08 ppm, respectively. The methyl carbons for the
compounds 2b, 2c and 2d were observed at 19.92, 21.37 and
20.42 ppm respectively. For the compounds 2a–2h, the aliphatic
carbons which were numbered as 12 in all compounds were
observed at 121.13, 121.30, 121.30, 121.10, 121.27, 121.12,
121.32 and 121.34 ppm respectively, while the aliphatic carbons
which were numbered as 13 in all compounds were observed at
144.06, 142.76, 145.40, 144.15, 143.84, 143.62, 137.86 and
140.61 ppm respectively.In vitro anti-tumor activity
The chalcone-phosphazene compounds synthesized were tested
for their in vitro anti-tumor activity against three cancer cell lines:
MCF-7 (human breast cancer cells), LNCaP (androgen-dependent
human prostate cancer cells) and PC-3 (androgen-independent
human prostate cancer cells) at five different concentrations (1, 5,
25, 50 and 100 lM) by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assay. The % cell viability of tested chal-
cone-phosphazene compounds are presented in Tables 1 and 2.
Figs. 4 and 5 shows the effects of the chalcone-phosphazene com-
pounds on cell viability measured at 24 h after exposure.
The chalcone-phosphazene compounds (2a–h) have anti-car-
cinogenic activity on PC-3 and LNCaP cell lines (p < 0.05). At
100 lM concentrations of all the compounds significantly reduced
the percentage of viability of PC-3 and LNCaP cells (⁄⁄p < 0.001).
The compounds 2d (p-methyl) showed more potent activity than
the compounds 2b (o-methyl) and 2c (m-methyl) against PC-3 cell
lines (Table 1). The compounds 2b (o-methyl) and 2c (m-methyl)
























































Fig. 3. 13C NMR spectrum of compound 2b (chloroform-d).
Table 1
Dose dependent cell-viability results in PC-3 cells after exposure to the chalcone-phosphazene compounds (2a–2h).
Groups Control 1 lM 5 lM 25 lM 50 lM 100 lM
2a 95.13 ± 1.99 88.27 ± 4.28 85.35 ± 5.01* 82.94 ± 2.97* 69.33 ± 4.01** 47.06 ± 3.11**
2b 95.13 ± 1.99 86.73 ± 7.06 86.25 ± 6.83 82.46 ± 5.4* 62.56 ± 2.42** 42.36 ± 6.49**
2c 95.13 ± 1.99 88.78 ± 6.41 89.61 ± 4.95 88.40 ± 7.23 80.57 ± 4.49** 54.56 ± 3.39**
2d 95.13 ± 1.99 87.33 ± 3.40* 87.49 ± 4.06* 87.43 ± 3.44* 73.84 ± 4.02** 52.28 ± 4.33**
2e 95.13 ± 1.99 88.28 ± 2.57 85.91 ± 5.39* 82.45 ± 4.08* 73.97 ± 2.92** 54.56 ± 3.39**
2f 95.13 ± 1.99 82.78 ± 5.0* 83.88 ± 3.34* 81.73 ± 6.86* 64.83 ± 6.1** 43.71 ± 3.02**
2g 95.13 ± 1.99 85.65 ± 5.9 84.87 ± 4.04* 82.53 ± 9.16* 64.71 ± 6.92** 35.93 ± 5.04**
2h 95.13 ± 1.99 90.12 ± 4.18 90.97 ± 6.18 88.07 ± 5.62* 66.57 ± 2.41** 51.45 ± 4.97**
* p < 0.05.
** p < 0.001.
Table 2
Dose dependent cell-viability results in LNCaP cells after exposure to the chalcone-phosphazene compounds (2a–2h).
Groups Control 1 lM 5 lM 25 lM 50 lM 100 lM
2a 93.37 ± 2.39 87.98 ± 4.84 84.07 ± 13.72* 80.04 ± 5.66* 79.84 ± 5.85** 62.51 ± 2.53**
2b 93.37 ± 2.39 77.93 ± 8.84* 75.05 ± 9.87* 74.95 ± 4.16* 69.55 ± 5.67** 69.04 ± 5.95**
2c 93.37 ± 2.39 88.58 ± 7.94 87.85 ± 2.50 83.79 ± 5.42* 82.21 ± 4.47* 77.83 ± 4.54**
2d 93.37 ± 2.39 86.06 ± 3.95 87.23 ± 6.11 91.13 ± 16.01 77.98 ± 9.86* 68.14 ± 6.37**
2e 93.37 ± 2.39 80.65 ± 5.96* 80.47 ± 9.42* 78.71 ± 6.01* 77.37 ± 6.41** 63.66 ± 2.67**
2f 93.37 ± 2.39 81.53 ± 4.82* 79.88 ± 7.65* 81.97 ± 4.45* 78.42 ± 9.67* 63.78 ± 3.43**
2g 93.37 ± 2.39 84.30 ± 10.47* 84.19 ± 3.79* 77.15 ± 12.85* 68.62 ± 5.66** 57.66 ± 6.36**
2h 93.37 ± 2.39 89.37 ± 7.50 87.69 ± 4.69 86.90 ± 5.19 76.16 ± 3.88** 64.79 ± 6.36**
* p < 0.05.
** p < 0.001.
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Fig. 4. The relative cell viability (%) of PC-3 cells following the exposure of various concentrations of all the compounds (2a–2h) and untreated control cell for 24 h (⁄p < 0.05;
⁄⁄p < 0.001).
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Fig. 5. The relative cell viability (%) of LNCaP cells following the exposure of various concentrations of all the compounds (2a–2h) and untreated control cell for 24 h
(⁄p < 0.05; ⁄⁄p < 0.001).
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against LNCaP cell lines (Table 2). The chalcone-phosphazene com-
pounds (2e, 2f and 2g) bearing a fluorine atom exhibited better
activity than other the chalcone-phosphazene compounds. In
general, chalcone derivatives exhibit anti-cancer activity [39–44].
But, there are no studies about anti-cancer properties of
chalcone-cyclophosphazene compounds. Our study of chalcone-
cyclophosphazenes is the first on human breast (MCF-7) and
prostate (LNCaP and PC-3) cancer cells. These results displayed
that cyclophosphazene bearing chalcone compounds may be used
as chemotherapy drug.Conclusions
In summary, the chalcone-cyclophosphazene compounds
(2a–2h) containing dioxybiphenyl groups were synthesized for
the first time by using of K2CO3/acetone system. All chalcone-phos-
phazene compounds (2a–2h) were generally resulted in high
yields. The synthesized chalcone phosphazene compounds were
characterized by elemental analysis, FT-IR, 31P, 1H, 13C NMR
techniques. All chalcone-phosphazene compounds (2a–2h) were
evaluated in vitro for their anticancer activity by MTT assay. The
chalcone-phosphazene compounds (2a–2h) have not antitumor
activity on MCF-7 (p > 0.05). All compounds showed highest anti-
tumor activity against PC-3 and LNCaP cell lines (p < 0.001). These
results displayed that cyclophosphazene bearing chalcone com-
pounds may be useful for anticancer drug development in the
future.
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